MEDP

AI Memo

Medpace

As of 2026-06-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 print will test awards momentum and book-to-bill recovery • 2026-07-22

Expected move: +9%

Biggest risk

The near-term debate is that Q1 book-to-bill was only 0.88x and net income margin fell to 17.5% from 20.5% a year earlier, while the President transition and new operations structure add an execution variable [#SEC-8K-2026-04-22] [#8-K-2026-06-04]. If awards stay sub-1x or margins compress again, MEDP could remain de-rated despite strong historical growth.

Invalidation

Break below $395 or thesis failure.

What would change my mind?

Primary evidence is fundamentally constructive: Q1 revenue rose 26.5% to $706.6 million, net new awards rose 23.7% to $618.4 million, EBITDA rose 25.9% to $149.4 million, and operating cash flow was $151.8 million [#SEC-8K-2026-04-22]. If Q2 shows book-to-bill normalization and unchanged or better guidance, the stock can regain a premium multiple.

Research note

Recommendation

—

Confidence

medium

As of

2026-06-18

Base target

$503

p=45%

Bull target

$540

p=30%

Bear target

$395

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Operations leadership transition needs clean execution
Backlog conversion, margin stability, and cash generation can support rerating
Primary evidence is fundamentally constructive: Q1 revenue rose 26.5% to $706.6 million, net new awards rose 23.7% to $618.4 million, EBITDA rose 25.9% to $149.4 million, and operating cash flow was $151.8 million [#SEC-8K-2026-04-22].

BearKey bullets

Clinical CRO competition remains intense; Medpace identifies IQVIA, ICON, PPD/Thermo Fisher, Fortrea, and specialty/regional CROs as key competitors [#10-K-2026-02-10].
Leadership changes around the President role and expanded operations leadership create execution-monitoring risk even though filings say the departure was not due to disagreement.
Net income margin fell year over year in Q1, so cost discipline and mix need to hold if growth moderates.

WatchKey bullets

Q2 2026 print will test awards momentum and book-to-bill recovery

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $503 (p=45%)

Bull/Bear spread: +17% / -14%

Vs latest close: Bull +17% · Base +9% · Bear -14%

Scenario probabilities

Bull Target: $540 (p=30%)Base Target: $503 (p=45%)Bear Target: $395 (p=25%)

Commentary

Primary-source evidence is strong, but the setup still reads as a monitoring-style positive rather than a clean momentum call. News flow over the last 30 days has been dominated by the Q1 release, the June leadership update, and the announced July 22 Q2 report date. The stock's $457.09 anchor sits above the post-earnings weakness referenced in secondary coverage, suggesting some recovery, but the market still appears to want proof that awards and margins can both hold into Q2. Analyst revision detail is not available in the packet, which lowers conviction somewhat despite solid company-reported fundamentals.

As of 2026-06-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Operations leadership transition needs clean execution
Backlog conversion, margin stability, and cash generation can support rerating

Scenarios

Bull Target (Scenario probability)

$540 / p=30% prob

Base Target (Scenario probability)

$503 / p=45% prob

Bear Target (Scenario probability)

$395 / p=25% prob

Price $460 as of 2026-06-18

Nearest Scenario: Base (∆ 9%)

Targets vs latest close: Bull +17% · Base +9% · Bear -14%

Sentiment & Exposure

News Sentiment (30d)

0.18

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-22
Q2 2026 print will test awards momentum and book-to-bill recovery
Medpace is scheduled to report Q2 2026 results on 2026-07-22; the key check is whether Q1 revenue growth of 26.5% and net new awards growth of 23.7% can convert into a book-to-bill back above the Q1 level of 0.88x while management holds 2026 guidance [#SEC-8K-2026-04-22].
Prob 70.00% • Move 9.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Operations leadership transition needs clean execution
2026-09-30
Brad Hansman was appointed Executive Vice President, Operations effective 2026-06-01 and will share principal operating officer duties; his background spans study start-up, logistics, regulatory affairs, and medical writing, so investors will watch for continuity in trial execution and sponsor service levels [#8-K-2026-06-04].
Prob 60% • Move 4% • Priced-in 60%

Long-term Catalysts

Months to a year

Backlog conversion, margin stability, and cash generation can support rerating
2026-12-31
Q1 backlog reached $2.93 billion, operating cash flow was $151.8 million, and full-year revenue guidance remains $2.755-$2.855 billion; if Medpace sustains conversion and protects EBITDA margin near the Q1 21.1% level, the market can re-rate the stock despite current caution around booking cadence [#SEC-8K-2026-04-22].
Prob 58% • Move 12% • Priced-in 50%

Risks

Clinical CRO competition remains intense; Medpace identifies IQVIA, ICON, PPD/Thermo Fisher, Fortrea, and specialty/regional CROs as key competitors [#10-K-2026-02-10].
Leadership changes around the President role and expanded operations leadership create execution-monitoring risk even though filings say the departure was not due to disagreement.
Net income margin fell year over year in Q1, so cost discipline and mix need to hold if growth moderates.
Sub-1.0x book-to-bill can pressure backlog confidence and reduce visibility on later-2026 revenue conversion.

Peers

Symbol	Summary
IQV	Direct CRO peer explicitly named by Medpace as a major competitor in its 2025 10-K competition section, making it a more relevant operating comp than broad biotech issuers [#10-K-2026-02-10].
ICLR	ICON is also listed by Medpace as a major full-service CRO competitor, useful for comparing booking cadence, backlog conversion, and margin durability [#10-K-2026-02-10].
FTRE	Fortrea is another named CRO competitor in Medpace's 2025 10-K and is relevant for reading sponsor demand and outsourcing trends across clinical development services [#10-K-2026-02-10].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-18

AI Stock Memo: MEDP - Medpace - RankAlpha